Related Experiment Video

Updated: Aug 16, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

Mild cognitive impairment and preclinical Alzheimer's disease

John C Morris1

  • 1Department of Neurology, Washington University School of Medicine, 4488 Forest Park Avenue, Suite 101, St. Louis, MO 63108, USA. morrisj@abraxas.wustl.edu

Geriatrics
|July 20, 2005
PubMed

Insights

Researchers are developing treatments and biomarkers for Alzheimer's disease (AD) and mild cognitive impairment (MCI). Early detection and intervention aim to preserve cognitive function and manage neurodegeneration.

Area of Science:

  • Neuroscience
  • Gerontology
  • Pathology

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder leading to dementia.
  • Mild cognitive impairment (MCI) signifies early memory deficits, often preceding AD.
  • Intervening during MCI offers a critical window for preserving cognitive function.

Purpose of the Study:

  • To explore disease-modifying treatments for MCI and AD.
  • To identify early biomarkers for AD detection before irreversible brain damage.
  • To improve management strategies for early-stage dementia.

Main Methods:

  • Investigating pathobiologic processes underlying MCI and AD.
  • Developing and validating novel antecedent biomarkers for AD.
  • Clinical research focused on early intervention and disease modification.

Main Results:

  • Current research focuses on therapeutic targets for MCI and AD.
  • Biomarker discovery aims for pre-symptomatic AD detection.
  • Therapeutic strategies seek to halt or slow neurodegenerative progression.

Conclusions:

  • Early intervention in MCI is crucial for managing Alzheimer's disease.
  • Biomarker development is key for timely AD diagnosis and treatment.
  • Research efforts are directed towards disease modification and cognitive preservation.

More Related Videos

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...